Clinical significance of phospholipid-dependent anti-β2-glycoprotein I (β2-GPI) antibodies in systemic lupus erythematosus

Abstract

We investigated the clinical significance of IgG phospholipid-dependent anti-β₂-glycoprotein I (β₂-GPI) antibodies in patients with SLE. The study population consisted of 140 patients with SLE. Sera were examined for IgG phospholipid-dependent anti-β₂-GPI antibodies by ELISA. IgG phospholipid-dependent anti-β₂-GPI antibodies were detected in 21 of 140 patients (15%) and remained positive from 4 to 98 months. Significantly higher incidences of thrombosis, intrauterine fetal loss, thrombocytopenia, patients with antiphospholipid syndrome (APS), prolonged APTT, BFP-STS and hemolytic anemia were found in SLE patients with phospholipid-dependent anti-β₂-GPI antibodies. Moreover, significantly lower incidences of malar rash and serositis were found in SLE patients with phospholipid-dependent anti-β₂-GPI antibodies, and the majority of these patients satisfied four or five of the revised criteria items of the American Rheumatism Association. These differences were not observed when we compared clinical manifestations in anticardiolipin antibody-positive patients with those in antibody-negative patients by conventional ELISA. These results indicated that SLE patients with IgG phospholipid-dependent anti-β₂-GPI antibodies show an unique form of SLE.

Keywords

anticardiolipin antibodies anti-β2-glycoprotein I antibodies antiphospholipid syndrome

Get full access to this article

View all access options for this article.

References

Harris EN , Gharavi AE , Hughes Grv. Anti-phospholipid antibodies. Clin Rheum Dis 1985; 11: 591-609.

Hughes Grv , Harris EN , Gharavi AE The anticardiolipin syndrome. J Rheumatol 1986; 13: 486-489.

Alarcón-Segovia D. et al. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients. Medicine 1989 ; 68: 353-365.

Love PE , Santoro SA Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance. Ann Intern Med 1990 ; 112: 682-698.

Harris EN , Hughes Grv. Antiphospholipid antibodies. In: McCarty DJ (ed.). Arthritis and Allied Conditions. Philadelphia: Lea & Febiger, 1989, pp 1068-1079.

Harris EN et al. Thrombosis, recurrent fetal loss and thrombocytopenia. Predictive value of the anticardiolipin antibody test. Arch Intern Med 1986; 146: 2153-2156.

Gharavi AE et al. Anticardiolipin antibodies: isotype distribution and phospholipid specificity. Ann Rheum Dis 1987; 46: 1-6.

Ishii Y. et al. Clinical importance of persistence of anticardiolipin antibodies in systemic lupus erythematosus. Ann Rheum Dis 1990; 49: 387-390.

McNeil HP et al. Antiphospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990; 87: 4120-4124.

10.

Galli M. et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990 ; 335: 1544-1547.

11.

Matsuura E. et al. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet 1990 ; 336: 177-178 (letter).

12.

Matsuura E. et al. Heterogeneity of anticardiolipin antibodies defined by the anticardiolipin cofactor. J Immunol 1992; 148: 3885-3891.

13.

Matsuura E. et al. Anticardiolipin antibodies recognize β2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface . J Exp Med 1994; 179: 457-462.

14.

Harris EN et al. Evaluation of the anti-cardiolipin antibody test: report of an international workshop held 4 April 1986. Clin Exp Immunol 1987; 68: 215-222.

15.

Kaburaki J. et al. Cofactor (β2-glycoprotein I) dependent anticardiolipin antibodies and thrombosis. J Rheumatol 1994; 21: 1371 (letter).

16.

Aoki K. et al. Clinical significance of β2-glycoprotein I-dependent anticardiolipin antibodies in the reproductive autoimmune failure syndrome: correlation with conventional antiphospholipid antibody detection systems. J Obstet Gynecol 1995; 172: 926-931.

17.

Kaburaki J. et al. Disease distribution of β2-glycoprotein I-dependent anticardiolipin antibodies in rheumatic diseases. Lupus 1995; 4: S27-S31.

18.

Tan EM et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.

19.

Koh SC et al. Anticardiolipin antibodies and platelets in pregnant subjects with systemic lupus erythematosus (SLE). J Med Lab Sci 1990; 4: 25-28.

20.

Blank M. et al. Immunization with anticardiolipin cofactor (beta-2-glycoprotein I) induces experimental antiphospholipid syndrome in naive mice. J Autoimmun 1994; 7: 441-455.

21.

Vermylen J. , Arnout J.

Is the antiphospholipid syndrome caused by antibodies directed against physiologically relevant phospholipid-protein complexes?

J Lab Clin Med 1992; 120: 10-12.

22.

Viard J-P. , Amoura Z. , Bach J-F. Association of anti-β2 glycoprotein I antibodies with lupus-type circulating anticoagulant and thrombosis in systemic lupus erythematosus. Am J Med 1992; 93: 181-186.

23.

Cohnen G. Immunochemical quantitation of β2-glycoprotein I in various diseases. J Lab Clin Med 1970; 75: 212-216.

24.

Edworthy S. et al. Analysis of the 1982 ARA lupus criteria data set by recursive partitioning methodology: new insights into the relative merit of individual criteria. J Rheumatol 1988; 15: 1493-1498.

25.

Asherson RA , Hughes Grv. Systemic lupus erythematosus, clinical features . In: Schumacher HR (ed.). Primer on the Rheumatic Diseases. Arthritis Foundation: Atlanta , 1988, pp 100-107.